ProPhase Labs (NASDAQ:PRPH) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of ProPhase Labs (NASDAQ:PRPHGet Rating) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Other equities analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of ProPhase Labs from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a report on Tuesday, February 22nd. HC Wainwright boosted their target price on shares of ProPhase Labs from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, March 31st. Finally, TheStreet upgraded shares of ProPhase Labs from a “d+” rating to a “c-” rating in a report on Monday, March 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, ProPhase Labs presently has a consensus rating of “Hold” and an average price target of $11.88.

Shares of ProPhase Labs stock opened at $7.12 on Thursday. The company has a market capitalization of $110.26 million and a PE ratio of 18.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.65 and a current ratio of 3.95. The company has a 50-day simple moving average of $7.18 and a two-hundred day simple moving average of $6.86. ProPhase Labs has a one year low of $4.44 and a one year high of $8.58.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in shares of ProPhase Labs during the third quarter valued at about $119,000. HighVista Strategies LLC acquired a new position in shares of ProPhase Labs during the third quarter valued at about $105,000. Geode Capital Management LLC increased its holdings in shares of ProPhase Labs by 3.1% during the third quarter. Geode Capital Management LLC now owns 105,857 shares of the company’s stock valued at $550,000 after acquiring an additional 3,152 shares in the last quarter. Perritt Capital Management Inc. increased its holdings in shares of ProPhase Labs by 5.9% during the third quarter. Perritt Capital Management Inc. now owns 188,400 shares of the company’s stock valued at $980,000 after acquiring an additional 10,500 shares in the last quarter. Finally, Avidian Wealth Solutions LLC increased its holdings in ProPhase Labs by 91.4% in the 3rd quarter. Avidian Wealth Solutions LLC now owns 105,202 shares of the company’s stock worth $547,000 after buying an additional 50,239 shares during the period. Hedge funds and other institutional investors own 9.75% of the company’s stock.

ProPhase Labs Company Profile (Get Rating)

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Recommended Stories

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.